A Phase 2, Observer-Blind, Placebo-Controlled, Proof-of-concept Trial to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients

Grants and Contracts Details

StatusFinished
Effective start/end date3/25/24 → 6/25/24

Funding

  • ModernaTX Incorporated: $10,000.00